Global Valvular Heart Diseases Treatment Market

Valvular Heart Diseases Treatment Comprehensive Study by Application (Congenital Heart Disease, Valve Stenosis, Valve Regurgitation, Others), Treatment (Surgery, Medication), Route of Administration (Oral, Intravenous, Others), Drug Class (Diuretics, Anti-Arrhythmic Medications, Vasodilators, ACE Inhibitors, Beta-Blockers, Anticoagulants, Others), End User (Ambulatory Surgical Centers & Hospitals, Specialty Clinics) Players and Region - Global Market Outlook to 2026

Valvular Heart Diseases Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Valvular Heart Diseases Treatment Market Scope
Valvular heart disease is when any valve in the heart has damaged or is diseased. There are several causes of valvular heart disease, including congenital conditions (being born with it), infections, degenerative conditions (wearing out with age), and conditions linked to other types of heart disease. The Valvular Heart Diseases Treatment market is expected to grow in the future due to rising research & development in valve replacement and adult cardiac surgery such as treatment for valvular heart diseases. Improvement of healthcare infrastructure in developing economies is boosting the marketing forecasted period.

The Valvular Heart Diseases Treatment market study is segmented, by Application (Congenital Heart Disease, Valve Stenosis, Valve Regurgitation and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Valvular Heart Diseases Treatment market throughout the predicted period.

Boston Scientific Corporation (United States), B. Braun Melsungen AG (Germany), Abbott Laboratories (United States), Medtronic (Ireland), CryoLife Inc. (United States), LivaNova Plc (United Kingdom), Micro Interventional Devices Inc (United States), Cook Medical Inc (United States) and Neovasc, Inc. (Canada) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are LifeNet Health (United States) and Edwards Lifesciences Corporation (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Valvular Heart Diseases Treatment market by Type, Application and Region.

On the basis of geography, the market of Valvular Heart Diseases Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In Jan 2019, Abbott announced that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately-held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease.
In April 2019, Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge™ Aortic Valve System.


Market Trend
  • Adoption of Advanced Technology in the Valvular Heart Diseases Treatment

Market Drivers
  • Increase in the Number of Cases of Coronary Artery Disease
  • Growing Geriatric Population

Opportunities
  • Growth in the Healthcare Industry Worldwide
  • Increasing Investment in Research and Development

Restraints
  • Higher Cost of Treatment & Devices

Challenges
  • Complex Regulatory Procedures


Key Target Audience
New Entrants/Investors, Healthcare Industry Associations, Venture Capitalists and Private Equity Firms, Valvular Heart Diseases Treatment Provider, Raw Material Suppliers, End-Use Industries and Analysts and Strategic Business Planners

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Report Objectives / Segmentation Covered

By Application
  • Congenital Heart Disease
  • Valve Stenosis
  • Valve Regurgitation
  • Others
By Treatment
  • Surgery
  • Medication

By Route of Administration
  • Oral
  • Intravenous
  • Others

By Drug Class
  • Diuretics
  • Anti-Arrhythmic Medications
  • Vasodilators
  • ACE Inhibitors
  • Beta-Blockers
  • Anticoagulants
  • Others

By End User
  • Ambulatory Surgical Centers & Hospitals
  • Specialty Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Number of Cases of Coronary Artery Disease
      • 3.2.2. Growing Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Complex Regulatory Procedures
    • 3.4. Market Trends
      • 3.4.1. Adoption of Advanced Technology in the Valvular Heart Diseases Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Valvular Heart Diseases Treatment, by Application, Treatment, Route of Administration, Drug Class, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Valvular Heart Diseases Treatment (Value)
      • 5.2.1. Global Valvular Heart Diseases Treatment by: Application (Value)
        • 5.2.1.1. Congenital Heart Disease
        • 5.2.1.2. Valve Stenosis
        • 5.2.1.3. Valve Regurgitation
        • 5.2.1.4. Others
      • 5.2.2. Global Valvular Heart Diseases Treatment by: Treatment (Value)
        • 5.2.2.1. Surgery
        • 5.2.2.2. Medication
      • 5.2.3. Global Valvular Heart Diseases Treatment by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Intravenous
        • 5.2.3.3. Others
      • 5.2.4. Global Valvular Heart Diseases Treatment by: Drug Class (Value)
        • 5.2.4.1. Diuretics
        • 5.2.4.2. Anti-Arrhythmic Medications
        • 5.2.4.3. Vasodilators
        • 5.2.4.4. ACE Inhibitors
        • 5.2.4.5. Beta-Blockers
        • 5.2.4.6. Anticoagulants
        • 5.2.4.7. Others
      • 5.2.5. Global Valvular Heart Diseases Treatment by: End User (Value)
        • 5.2.5.1. Ambulatory Surgical Centers & Hospitals
        • 5.2.5.2. Specialty Clinics
      • 5.2.6. Global Valvular Heart Diseases Treatment Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Valvular Heart Diseases Treatment (Price)
  • 6. Valvular Heart Diseases Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Boston Scientific Corporation (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. B. Braun Melsungen AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Medtronic (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. CryoLife Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. LivaNova Plc (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Micro Interventional Devices Inc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cook Medical Inc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Neovasc, Inc. (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Valvular Heart Diseases Treatment Sale, by Application, Treatment, Route of Administration, Drug Class, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Valvular Heart Diseases Treatment (Value)
      • 7.2.1. Global Valvular Heart Diseases Treatment by: Application (Value)
        • 7.2.1.1. Congenital Heart Disease
        • 7.2.1.2. Valve Stenosis
        • 7.2.1.3. Valve Regurgitation
        • 7.2.1.4. Others
      • 7.2.2. Global Valvular Heart Diseases Treatment by: Treatment (Value)
        • 7.2.2.1. Surgery
        • 7.2.2.2. Medication
      • 7.2.3. Global Valvular Heart Diseases Treatment by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Intravenous
        • 7.2.3.3. Others
      • 7.2.4. Global Valvular Heart Diseases Treatment by: Drug Class (Value)
        • 7.2.4.1. Diuretics
        • 7.2.4.2. Anti-Arrhythmic Medications
        • 7.2.4.3. Vasodilators
        • 7.2.4.4. ACE Inhibitors
        • 7.2.4.5. Beta-Blockers
        • 7.2.4.6. Anticoagulants
        • 7.2.4.7. Others
      • 7.2.5. Global Valvular Heart Diseases Treatment by: End User (Value)
        • 7.2.5.1. Ambulatory Surgical Centers & Hospitals
        • 7.2.5.2. Specialty Clinics
      • 7.2.6. Global Valvular Heart Diseases Treatment Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Valvular Heart Diseases Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Valvular Heart Diseases Treatment: by Application(USD Million)
  • Table 2. Valvular Heart Diseases Treatment Congenital Heart Disease , by Region USD Million (2015-2020)
  • Table 3. Valvular Heart Diseases Treatment Valve Stenosis , by Region USD Million (2015-2020)
  • Table 4. Valvular Heart Diseases Treatment Valve Regurgitation , by Region USD Million (2015-2020)
  • Table 5. Valvular Heart Diseases Treatment Others , by Region USD Million (2015-2020)
  • Table 6. Valvular Heart Diseases Treatment: by Treatment(USD Million)
  • Table 7. Valvular Heart Diseases Treatment Surgery , by Region USD Million (2015-2020)
  • Table 8. Valvular Heart Diseases Treatment Medication , by Region USD Million (2015-2020)
  • Table 9. Valvular Heart Diseases Treatment: by Route of Administration(USD Million)
  • Table 10. Valvular Heart Diseases Treatment Oral , by Region USD Million (2015-2020)
  • Table 11. Valvular Heart Diseases Treatment Intravenous , by Region USD Million (2015-2020)
  • Table 12. Valvular Heart Diseases Treatment Others , by Region USD Million (2015-2020)
  • Table 13. Valvular Heart Diseases Treatment: by Drug Class(USD Million)
  • Table 14. Valvular Heart Diseases Treatment Diuretics , by Region USD Million (2015-2020)
  • Table 15. Valvular Heart Diseases Treatment Anti-Arrhythmic Medications , by Region USD Million (2015-2020)
  • Table 16. Valvular Heart Diseases Treatment Vasodilators , by Region USD Million (2015-2020)
  • Table 17. Valvular Heart Diseases Treatment ACE Inhibitors , by Region USD Million (2015-2020)
  • Table 18. Valvular Heart Diseases Treatment Beta-Blockers , by Region USD Million (2015-2020)
  • Table 19. Valvular Heart Diseases Treatment Anticoagulants , by Region USD Million (2015-2020)
  • Table 20. Valvular Heart Diseases Treatment Others , by Region USD Million (2015-2020)
  • Table 21. Valvular Heart Diseases Treatment: by End User(USD Million)
  • Table 22. Valvular Heart Diseases Treatment Ambulatory Surgical Centers & Hospitals , by Region USD Million (2015-2020)
  • Table 23. Valvular Heart Diseases Treatment Specialty Clinics , by Region USD Million (2015-2020)
  • Table 24. South America Valvular Heart Diseases Treatment, by Country USD Million (2015-2020)
  • Table 25. South America Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 26. South America Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 27. South America Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 28. South America Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 29. South America Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 30. Brazil Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 31. Brazil Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 32. Brazil Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 33. Brazil Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 34. Brazil Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 35. Argentina Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 36. Argentina Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 37. Argentina Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 38. Argentina Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 39. Argentina Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 40. Rest of South America Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 41. Rest of South America Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 42. Rest of South America Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 43. Rest of South America Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 44. Rest of South America Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 45. Asia Pacific Valvular Heart Diseases Treatment, by Country USD Million (2015-2020)
  • Table 46. Asia Pacific Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 47. Asia Pacific Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 48. Asia Pacific Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 49. Asia Pacific Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 50. Asia Pacific Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 51. China Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 52. China Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 53. China Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 54. China Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 55. China Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 56. Japan Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 57. Japan Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 58. Japan Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 59. Japan Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 60. Japan Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 61. India Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 62. India Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 63. India Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 64. India Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 65. India Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 66. South Korea Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 67. South Korea Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 68. South Korea Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 69. South Korea Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 70. South Korea Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 71. Taiwan Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 72. Taiwan Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 73. Taiwan Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 74. Taiwan Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 75. Taiwan Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 76. Australia Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 77. Australia Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 78. Australia Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 79. Australia Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 80. Australia Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 83. Rest of Asia-Pacific Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 84. Rest of Asia-Pacific Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 85. Rest of Asia-Pacific Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 86. Europe Valvular Heart Diseases Treatment, by Country USD Million (2015-2020)
  • Table 87. Europe Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 88. Europe Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 89. Europe Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 90. Europe Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 91. Europe Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 92. Germany Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 93. Germany Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 94. Germany Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 95. Germany Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 96. Germany Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 97. France Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 98. France Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 99. France Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 100. France Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 101. France Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 102. Italy Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 103. Italy Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 104. Italy Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 105. Italy Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 106. Italy Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 107. United Kingdom Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 108. United Kingdom Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 109. United Kingdom Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 110. United Kingdom Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 111. United Kingdom Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 112. Netherlands Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 113. Netherlands Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 114. Netherlands Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 115. Netherlands Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 116. Netherlands Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 117. Rest of Europe Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 118. Rest of Europe Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 119. Rest of Europe Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 120. Rest of Europe Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 121. Rest of Europe Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 122. MEA Valvular Heart Diseases Treatment, by Country USD Million (2015-2020)
  • Table 123. MEA Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 124. MEA Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 125. MEA Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 126. MEA Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 127. MEA Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 128. Middle East Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 129. Middle East Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 130. Middle East Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 131. Middle East Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 132. Middle East Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 133. Africa Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 134. Africa Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 135. Africa Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 136. Africa Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 137. Africa Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 138. North America Valvular Heart Diseases Treatment, by Country USD Million (2015-2020)
  • Table 139. North America Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 140. North America Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 141. North America Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 142. North America Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 143. North America Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 144. United States Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 145. United States Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 146. United States Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 147. United States Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 148. United States Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 149. Canada Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 150. Canada Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 151. Canada Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 152. Canada Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 153. Canada Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 154. Mexico Valvular Heart Diseases Treatment, by Application USD Million (2015-2020)
  • Table 155. Mexico Valvular Heart Diseases Treatment, by Treatment USD Million (2015-2020)
  • Table 156. Mexico Valvular Heart Diseases Treatment, by Route of Administration USD Million (2015-2020)
  • Table 157. Mexico Valvular Heart Diseases Treatment, by Drug Class USD Million (2015-2020)
  • Table 158. Mexico Valvular Heart Diseases Treatment, by End User USD Million (2015-2020)
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Valvular Heart Diseases Treatment: by Application(USD Million)
  • Table 169. Valvular Heart Diseases Treatment Congenital Heart Disease , by Region USD Million (2021-2026)
  • Table 170. Valvular Heart Diseases Treatment Valve Stenosis , by Region USD Million (2021-2026)
  • Table 171. Valvular Heart Diseases Treatment Valve Regurgitation , by Region USD Million (2021-2026)
  • Table 172. Valvular Heart Diseases Treatment Others , by Region USD Million (2021-2026)
  • Table 173. Valvular Heart Diseases Treatment: by Treatment(USD Million)
  • Table 174. Valvular Heart Diseases Treatment Surgery , by Region USD Million (2021-2026)
  • Table 175. Valvular Heart Diseases Treatment Medication , by Region USD Million (2021-2026)
  • Table 176. Valvular Heart Diseases Treatment: by Route of Administration(USD Million)
  • Table 177. Valvular Heart Diseases Treatment Oral , by Region USD Million (2021-2026)
  • Table 178. Valvular Heart Diseases Treatment Intravenous , by Region USD Million (2021-2026)
  • Table 179. Valvular Heart Diseases Treatment Others , by Region USD Million (2021-2026)
  • Table 180. Valvular Heart Diseases Treatment: by Drug Class(USD Million)
  • Table 181. Valvular Heart Diseases Treatment Diuretics , by Region USD Million (2021-2026)
  • Table 182. Valvular Heart Diseases Treatment Anti-Arrhythmic Medications , by Region USD Million (2021-2026)
  • Table 183. Valvular Heart Diseases Treatment Vasodilators , by Region USD Million (2021-2026)
  • Table 184. Valvular Heart Diseases Treatment ACE Inhibitors , by Region USD Million (2021-2026)
  • Table 185. Valvular Heart Diseases Treatment Beta-Blockers , by Region USD Million (2021-2026)
  • Table 186. Valvular Heart Diseases Treatment Anticoagulants , by Region USD Million (2021-2026)
  • Table 187. Valvular Heart Diseases Treatment Others , by Region USD Million (2021-2026)
  • Table 188. Valvular Heart Diseases Treatment: by End User(USD Million)
  • Table 189. Valvular Heart Diseases Treatment Ambulatory Surgical Centers & Hospitals , by Region USD Million (2021-2026)
  • Table 190. Valvular Heart Diseases Treatment Specialty Clinics , by Region USD Million (2021-2026)
  • Table 191. South America Valvular Heart Diseases Treatment, by Country USD Million (2021-2026)
  • Table 192. South America Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 193. South America Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 194. South America Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 195. South America Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 196. South America Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 197. Brazil Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 198. Brazil Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 199. Brazil Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 200. Brazil Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 201. Brazil Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 202. Argentina Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 203. Argentina Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 204. Argentina Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 205. Argentina Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 206. Argentina Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 207. Rest of South America Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 208. Rest of South America Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 209. Rest of South America Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 210. Rest of South America Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 211. Rest of South America Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 212. Asia Pacific Valvular Heart Diseases Treatment, by Country USD Million (2021-2026)
  • Table 213. Asia Pacific Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 214. Asia Pacific Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 215. Asia Pacific Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 216. Asia Pacific Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 217. Asia Pacific Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 218. China Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 219. China Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 220. China Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 221. China Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 222. China Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 223. Japan Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 224. Japan Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 225. Japan Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 226. Japan Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 227. Japan Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 228. India Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 229. India Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 230. India Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 231. India Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 232. India Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 233. South Korea Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 234. South Korea Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 235. South Korea Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 236. South Korea Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 237. South Korea Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 238. Taiwan Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 239. Taiwan Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 240. Taiwan Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 241. Taiwan Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 242. Taiwan Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 243. Australia Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 244. Australia Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 245. Australia Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 246. Australia Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 247. Australia Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 248. Rest of Asia-Pacific Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 249. Rest of Asia-Pacific Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 250. Rest of Asia-Pacific Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 251. Rest of Asia-Pacific Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 252. Rest of Asia-Pacific Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 253. Europe Valvular Heart Diseases Treatment, by Country USD Million (2021-2026)
  • Table 254. Europe Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 255. Europe Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 256. Europe Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 257. Europe Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 258. Europe Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 259. Germany Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 260. Germany Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 261. Germany Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 262. Germany Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 263. Germany Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 264. France Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 265. France Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 266. France Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 267. France Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 268. France Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 269. Italy Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 270. Italy Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 271. Italy Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 272. Italy Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 273. Italy Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 274. United Kingdom Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 275. United Kingdom Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 276. United Kingdom Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 277. United Kingdom Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 278. United Kingdom Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 279. Netherlands Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 280. Netherlands Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 281. Netherlands Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 282. Netherlands Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 283. Netherlands Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 284. Rest of Europe Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 285. Rest of Europe Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 286. Rest of Europe Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 287. Rest of Europe Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 288. Rest of Europe Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 289. MEA Valvular Heart Diseases Treatment, by Country USD Million (2021-2026)
  • Table 290. MEA Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 291. MEA Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 292. MEA Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 293. MEA Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 294. MEA Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 295. Middle East Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 296. Middle East Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 297. Middle East Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 298. Middle East Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 299. Middle East Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 300. Africa Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 301. Africa Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 302. Africa Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 303. Africa Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 304. Africa Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 305. North America Valvular Heart Diseases Treatment, by Country USD Million (2021-2026)
  • Table 306. North America Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 307. North America Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 308. North America Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 309. North America Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 310. North America Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 311. United States Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 312. United States Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 313. United States Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 314. United States Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 315. United States Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 316. Canada Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 317. Canada Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 318. Canada Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 319. Canada Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 320. Canada Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 321. Mexico Valvular Heart Diseases Treatment, by Application USD Million (2021-2026)
  • Table 322. Mexico Valvular Heart Diseases Treatment, by Treatment USD Million (2021-2026)
  • Table 323. Mexico Valvular Heart Diseases Treatment, by Route of Administration USD Million (2021-2026)
  • Table 324. Mexico Valvular Heart Diseases Treatment, by Drug Class USD Million (2021-2026)
  • Table 325. Mexico Valvular Heart Diseases Treatment, by End User USD Million (2021-2026)
  • Table 326. Research Programs/Design for This Report
  • Table 327. Key Data Information from Secondary Sources
  • Table 328. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Valvular Heart Diseases Treatment: by Application USD Million (2015-2020)
  • Figure 5. Global Valvular Heart Diseases Treatment: by Treatment USD Million (2015-2020)
  • Figure 6. Global Valvular Heart Diseases Treatment: by Route of Administration USD Million (2015-2020)
  • Figure 7. Global Valvular Heart Diseases Treatment: by Drug Class USD Million (2015-2020)
  • Figure 8. Global Valvular Heart Diseases Treatment: by End User USD Million (2015-2020)
  • Figure 9. South America Valvular Heart Diseases Treatment Share (%), by Country
  • Figure 10. Asia Pacific Valvular Heart Diseases Treatment Share (%), by Country
  • Figure 11. Europe Valvular Heart Diseases Treatment Share (%), by Country
  • Figure 12. MEA Valvular Heart Diseases Treatment Share (%), by Country
  • Figure 13. North America Valvular Heart Diseases Treatment Share (%), by Country
  • Figure 14. Global Valvular Heart Diseases Treatment share by Players 2020 (%)
  • Figure 15. Global Valvular Heart Diseases Treatment share by Players (Top 3) 2020(%)
  • Figure 16. Global Valvular Heart Diseases Treatment share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. Boston Scientific Corporation (United States) Revenue: by Geography 2020
  • Figure 20. B. Braun Melsungen AG (Germany) Revenue, Net Income and Gross profit
  • Figure 21. B. Braun Melsungen AG (Germany) Revenue: by Geography 2020
  • Figure 22. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 23. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 24. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 25. Medtronic (Ireland) Revenue: by Geography 2020
  • Figure 26. CryoLife Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. CryoLife Inc. (United States) Revenue: by Geography 2020
  • Figure 28. LivaNova Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. LivaNova Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 30. Micro Interventional Devices Inc (United States) Revenue, Net Income and Gross profit
  • Figure 31. Micro Interventional Devices Inc (United States) Revenue: by Geography 2020
  • Figure 32. Cook Medical Inc (United States) Revenue, Net Income and Gross profit
  • Figure 33. Cook Medical Inc (United States) Revenue: by Geography 2020
  • Figure 34. Neovasc, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 35. Neovasc, Inc. (Canada) Revenue: by Geography 2020
  • Figure 36. Global Valvular Heart Diseases Treatment: by Application USD Million (2021-2026)
  • Figure 37. Global Valvular Heart Diseases Treatment: by Treatment USD Million (2021-2026)
  • Figure 38. Global Valvular Heart Diseases Treatment: by Route of Administration USD Million (2021-2026)
  • Figure 39. Global Valvular Heart Diseases Treatment: by Drug Class USD Million (2021-2026)
  • Figure 40. Global Valvular Heart Diseases Treatment: by End User USD Million (2021-2026)
  • Figure 41. South America Valvular Heart Diseases Treatment Share (%), by Country
  • Figure 42. Asia Pacific Valvular Heart Diseases Treatment Share (%), by Country
  • Figure 43. Europe Valvular Heart Diseases Treatment Share (%), by Country
  • Figure 44. MEA Valvular Heart Diseases Treatment Share (%), by Country
  • Figure 45. North America Valvular Heart Diseases Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Boston Scientific Corporation (United States)
  • B. Braun Melsungen AG (Germany)
  • Abbott Laboratories (United States)
  • Medtronic (Ireland)
  • CryoLife Inc. (United States)
  • LivaNova Plc (United Kingdom)
  • Micro Interventional Devices Inc (United States)
  • Cook Medical Inc (United States)
  • Neovasc, Inc. (Canada)
Additional players considered in the study are as follows:
LifeNet Health (United States) , Edwards Lifesciences Corporation (United States)
Select User Access Type

Key Highlights of Report


Jan 2021 212 Pages 82 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Valvular Heart Diseases Treatment Market Quantitative research analysis
Global Valvular Heart Diseases Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Valvular Heart Diseases Treatment Market Report?

Have a Query? Click Here

Other Related Reports

High Tibial Osteotomy Comprehensive Study by Application (Hospitals, Ambulatory Surgical Centers), Material (Metals, Polymers), Technique (Open Wedge, Closed Wedge, Others) Players and Region - Globa...
$ 3500
Oocyte Cryopreservation Comprehensive Study by Type (Slow-cooling Method, Flash-freezing Process (Vitrification)), Application (25-30-Year-Old Female, 30-35-Year-Old Female, 35-40-Year-Old Female, Ot...
$ 3750
Wound Tissue Analysis Solutions Comprehensive Study by Application (Acute Wounds, Chronic Wounds, Burns, Ulcers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacies, Mail Order Pharma...
$ 3650
Keratosis Pilaris Treatment Comprehensive Study by Type (Rubra, Alba, Rubra Faceii), Treatment (Over-The-Counter, Prescription Medication, Exfoliating, Laser Treatments), Sales Channel (Online Pharma...
$ 3500
Canine Lymphoma Treatment Comprehensive Study by Drug (Alkylating agents, Corticosteroids, Purine Analogs, Antimetabolites, Immune Modulators, Others), Lymphoma (Multicentric lymphoma, Alimentary lym...
$ 3650
Cardiac Arrest Treatment Comprehensive Study by Application (Hospital, Cardiac Clinics, Ambulatory Surgical Centers), Drug (Vasopressors, Anti-arrhythmic Drugs, Anticholinergic Drugs, Antihypertensiv...
$ 3650